Breaking News

You are here » Indian-Commodity  :  Mutual Funds  :  UTI Mutual Fund introduces FTIF Series XXVIII-VI (1190 Days)

10-Jan2018

UTI Mutual Fund introduces FTIF Series XXVIII-VI (1190 Days)

UTI Mutual Fund has launched the UTI FTIF Series XXVIII-VI (1190 Days), a close ended income scheme. The NFO opens for subscription on January 10, 2018 and closes on January 11, 2018. No entry load and exit load will be applicable for the scheme. The minimum subscription amount is Rs 5000.

The scheme's performance will be benchmarked against CRISIL Composite Bond Fund Index and its fund manager is Sunil Patil.

The investment objective of the scheme is to generate returns by investing in portfolio of fixed income securities maturing on or before the date of maturity of the scheme.


Related News

View all news

Franklin Templeton Mutual Fund introduces Fixed Maturity Plans-Series 5-Plan B (1244 days)

Franklin Templeton Mutual Fund has launched the Franklin India Fixed Maturity Plans-Series 5-Plan B (1244 days), a close ended debt scheme. The NFO opens for subscription on November 19, 2018 and closes......

Aditya Birla Sun Life Mutual Fund introduces Fixed Term Plan-Series QQ (1100 days)

Aditya Birla Sun Life Mutual Fund has launched the Aditya Birla Sun Life Fixed Term Plan-Series QQ (1100 days), a close ended income scheme. The NFO opens for subscription on August 20, 2018 and closes......

Franklin Templeton Mutual Fund introduces Fixed Maturity Plans-Series 4-Plan C (1098 days)

Franklin Templeton Mutual Fund has launched the Franklin India Fixed Maturity Plans-Series 4-Plan C (1098 days), a close ended income scheme. The NFO opens for subscription on August 20, 2018 and closes......

Top News

View all news

Megastar Foods planning to incorporate subsidiary

Megastar Foods is planning to incorporate a subsidiary Company. The meeting of the Board of Directors of the company is scheduled to be held on November 27, 2018, to consider the same. Megastar Foods is......

Lupin launches generic Tetrabenazine Tablets

Lupin has launched Tetrabenazine Tablets, 12.5 mg and 25 mg having received an approval from the United States Food and Drug Administration (USFDA) earlier. Lupin's Tetrabenazine Tablets, 12.5 mg and 25......

UPL's arm signs definitive agreement to acquire entire stake of IBC

UPL's wholly owned subsidiary-- UPL Corporation, Mauritius has signed a definitive agreement to acquire directly or through its subsidiaries 100% of the shares of INDUSTRIAS BIOQUIM CENTROAMERICANA, SOCIEDAD......